Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close

Pressreleases

  • Rockland Announces General Release of BioQuantiPro™ Host Cell Protein Screening Kit for Bioprocessing

    Limerick, PA. September 4, 2018 – Rockland Immunochemicals, Inc. announced today the general release of their new BioQuantiPro™ CHO-HCP ELISA Kit for detection and screening of host cell protein (HCP) contaminants in bioprocessing. The kit was specifically designed with Rockland’s novel, validated antibodies to detect HCP contaminants and to measure analytes from crude cellular harvests, cell culture lysates, and process intermediates. The BioQuantiPro CHO-HCP ELISA Kit boasts the highest coverage of generic CHO-HCP kits, low variability, and, most importantly, the data to back it all up.

  • Rockland Immunochemicals, Inc. Awarded SBIR Funding for Systemic Pre-targeted Radioimmunothearpy with Bispecific Single Domain Antibodies for Cancer Treatment

    Limerick, PA. November 14th, 2016 – Rockland Immunochemicals, Inc. (Rockland) announced today the award of a $299,625 Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI) to develop bispecific single chain recombinant antibodies for pre-targeted cancer diagnostic imaging and treatment. The funds will be distributed among Rockland and its collaborators, Abzyme Therapeutics (Limerick, PA) and Dr. Carolyn Anderson of the University of Pittsburgh Medical Center (Pittsburgh, PA). This joint strategic effort will promote the generation of novel reagents and new insights for cancer imaging and therapeutic research.

  • Rockland Immunochemicals, Inc. Awarded SBIR Funding to Develop Antibody-Based Point of Care Device for the Diagnosis of Sickle Cell Disease

    Limerick, PA. September 8th, 2014 – Rockland Immunochemicals, Inc. (Rockland) announced today the award of a $224,473 Small Business Innovation Research (SBIR) grant from the NIH National Heart Lung and Blood Institute (NHLBI) to develop an antibody-based point of care device for the diagnosis of Sickle Cell Disease (SCD), a mutation that is carried in approximately 7% of the world’s population. Rockland secured the award by demonstrating the technology and processes it deploys to develop and to produce leading edge life science tools for basic and clinical research focused on functional genomics and drug discovery markets.

  • The Binding Site & Rockland Immunochemicals Enter into Distribution Agreement

    UK based specialist diagnostic manufacturer, The Binding Site Group Ltd, is pleased to announce that it has entered into an exclusive, definitive agreement with Rockland Immunochemicals, Inc., of Limerick, PA, to grant Rockland global distribution rights for Binding Site’s line of animal-focused radial immunodiffusion (RID) test kits. The availability of this unique range of products exclusively through Rockland will benefit the needs of laboratory professionals conducting basic, applied, and clinical research in the veterinary, biomedical, life-science, genomics, and drug discovery fields.

  • Rockland Immunochemicals, Inc. Partners with Alex’s Lemonade Stand Foundation to Support Early Career Childhood Cancer Researchers

    In a continuing effort in the fight against childhood cancer, Rockland awarded the Joy Cappel Young Investigator Award (JCYIA) to two Alex’s Lemonade Stand Foundation (ALSF) Young Investigator grantees. In addition, Rockland is donating over $150,000 in reagents for the projects of ALSF Young Investigator and ‘A’ Award grantees with active grants.

  • Formula Pharmaceuticals and Rockland Immunochemicals Enter Into a Collaboration To Develop C.I.K. CAR™ Immunotherapy Pipeline for the Treatment of Cancer

    Berwyn, PA, and Limerick, PA – February 22, 2016 – Formula Pharmaceuticals, Inc. and Rockland Immunochemicals, Inc. announced today the establishment of a collaboration for the preclinical development of Formula’s Cytokine Induced Killer (C.I.K.) cell-based Chimeric Antigen Receptor (CAR) cancer immunotherapies at Rockland’s R&D facility. Under the collaboration, Rockland will provide and manage Formula’s specially hired preclinical research team. Further, Rockland will provide the classified research facilities for Formula’s preclinical development needs in its newly established, scalable 60,000 sq ft R&D facility.

  • Rockland Immunochemicals Donates 100% of “Pink” Product Proceeds to Breastcancer.org

    Gilbertsville, PA. January 20th, 2014 – Rockland Immunochemicals Inc. today announced that it donated $6,700 to Breastcancer.org, based on the sales of “Pink products”. In October 2013, Rockland declared seven groups of products “pink” in an effort to support Breast Cancer Awareness Month. These product categories included a variety of conjugates, ATTO dyes and protein markers.

  • Rockland Hosts Meeting on STEM Job Creation with PA Officials and Regional Organizations

    September 14, 2015, Limerick, Pa. – On September 9th, Rockland Immunochemicals, Inc., conducted an event with leading representatives spanning Government, Non-Profit, Industry and Education. Attendees included Pennsylvania State Senator Bob Mensch, State Representative Tom Quigley, John Munera of State Senator John Rafferty, Jr.’s office, and officials from The Wistar Institute, Montgomery County Community College (MCCC), and PABio.